Teijin Pharma Limited.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Teijin Pharma Limited.
Takeda continued to prove largely resistant to the business impact of the pandemic last fiscal year, when it made solid progress and exceeded a number of post-Shire targets. R&D spending is set to ramp-up as the Japanese firm progresses its 'Wave 1' pipeline to market.
Glenmark is toasting another launch for the company’s Ryaltris novel treatment for allergic rhinitis, this time with plans to roll the product out in 17 countries across western Europe.
More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
- Rehabilitation Equipment and Devices
- Other Names / Subsidiaries
- MedTech Heart